Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease
- PMID: 17982610
Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease
Abstract
We present the case of an 18-year-old woman with Crohn's disease manifested by diffuse abdominal pain, bloody diarrhea accompanied by arthralgia, and swelling of large joints. On the lateral aspect of her right ankle there was an hemorrhagic, necrotic bullous lesion measuring 3 x 4 cm, surrounded by cutaneous inflammation and erythema. Biopsy showed a neutrophilic abscess-like ulcerative skin inflammation, which was diagnosed as pyoderma gangrenosum. The patient was treated with high doses of parenteral methylprednisolone, but her condition failed to improve and infliximab, a TNF-alpha blocking agent, was instituted. An immediate response of Crohn's disease was observed and, over the next 5 weeks, the ulcer on her right ankle also healed completely.
Similar articles
-
Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.Acta Dermatovenerol Croat. 2016 Apr;24(1):83-5. Acta Dermatovenerol Croat. 2016. PMID: 27149138
-
Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.Rom J Gastroenterol. 2005 Dec;14(4):401-3. Rom J Gastroenterol. 2005. PMID: 16400359
-
Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stone.World J Gastroenterol. 2009 May 14;15(18):2293-5. doi: 10.3748/wjg.15.2293. World J Gastroenterol. 2009. PMID: 19437575 Free PMC article.
-
[The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease].Acta Med Croatica. 2013 Apr;67(2):195-201. Acta Med Croatica. 2013. PMID: 24471303 Review. Croatian.
-
Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.Dermatology. 2007;215(3):245-51. doi: 10.1159/000106584. Dermatology. 2007. PMID: 17823524 Review.
Cited by
-
[Anti-TNF biologics in the treatment of chronic inflammatory bowel disease].Internist (Berl). 2008 Aug;49(8):947-8, 950-3. doi: 10.1007/s00108-008-2058-3. Internist (Berl). 2008. PMID: 18584139 Review. German.
-
Pure Bullous Pyoderma Gangrenosum, a Challenging Clinico-Pathological Diagnosis: Critical Literature Review with Emphasis on Diagnostic Criteria.Indian J Dermatol. 2022 Jul-Aug;67(4):409-414. doi: 10.4103/ijd.ijd_1133_20. Indian J Dermatol. 2022. PMID: 36578743 Free PMC article.
-
Canadian Association of Gastroenterology Clinical Practice Guidelines: The use of tumour necrosis factor-alpha antagonist therapy in Crohn's disease.Can J Gastroenterol. 2009 Mar;23(3):185-202. doi: 10.1155/2009/201430. Can J Gastroenterol. 2009. PMID: 19319383 Free PMC article.
-
Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.Int Wound J. 2019 Apr;16(2):511-521. doi: 10.1111/iwj.13067. Epub 2019 Jan 3. Int Wound J. 2019. PMID: 30604927 Free PMC article. Review.
-
Extraintestinal Manifestations of Inflammatory Bowel Disease.Inflamm Bowel Dis. 2015 Aug;21(8):1982-92. doi: 10.1097/MIB.0000000000000392. Inflamm Bowel Dis. 2015. PMID: 26154136 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical